Table 1.
Involvement of the FT in Patients With Invasive Pelvic Carcinomas and in High-Risk Population Undergoing Prophylactic BSO
| Study | No. of Patients |
BRCA Mutations Status
|
Pelvic Carcinoma
|
Involvement of FT
|
Extensive Sectioning | Comments | |||
|---|---|---|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | ||||
| Pelvic carcinoma | |||||||||
| Agoff et al70 | 7 | 4/7 | 57 | 7 | 100 | 5/7 | 71 | + | Diagnosis of two FT malignancies required peritoneal lavage |
| Piek et al71 | 50 | NA | 50/50 | 100 | 3/50 | 6 | NA | ||
| Kindelberger et al72 | 55 | NA | 55/55 | 100 | 41/55 | 75 | + | 93% of TICs occurred in the fimbria | |
| Carlson et al73 | 45 | NA | 45/45 Primary peritoneal carcinoma | 100 | 28/45 | 62 | ± | 26 cases had incomplete pathologic examination and the rate of tubal involvement was 50%, while the next 19 cases, which underwent extensive sectioning had tubal involvement rate of 79% | |
| High-risk prophylactic BSO v general population | |||||||||
| Carcangiu et al74 | 26 high-risk v 49 control BSOs | BRCA1, 22 | 85 | 2/26 | 7.7 | 2/2 | 100 | NA | |
| BRCA, 24 | 15 | ||||||||
| Medeiros et al75 | 13 v 13 control BSO | NA | 5/13 | 38 | 5/5 | 100 | + | 4/5 (80%) of cases involved the fimbria | |
| High-risk prophylactic BSO | |||||||||
| Lu et al76 | 50 | NA | 4/50 | 8 | 0/4 | + (37/50 cases) | |||
| Kauff et al77 | 98 | BRCA1, 56 | 57 | 0 | 0 | − | One case of primary peritoneal carcinoma 16.3 months after BSO | ||
| BRCA2, 42 | 43 | ||||||||
| Leeper et al78 | 30 | BRCA1, 19 | 63.5 | 5/30 | 16.6 | 3/5 | 60 | + | |
| BRCA2, 4 | 13.5 | ||||||||
| No mutation detected, 7 | 23 | ||||||||
| Colgan et al79 | 60 | 5/60 | 8 | 2/5 | 40 | + | |||
| Olopade et al80 | 98 | 98/98 | 3/98 | 3 | 0/3 | − | |||
| Olivier et al81 | 90 | BRCA1, 58 | 64 | 5/90 | 5.5 | 3/5 | 60 | + | Three additional cases of primary peritoneal cancer detected in follow-up; 38 additional high-risk patients underwent only prophylactic oophorectomy—no malignancies found |
| BRCA2, 6 | 7 | ||||||||
| Both BRCA1/2, 1 | 1 | ||||||||
| Not specified, 25 | 28 | ||||||||
| Powell et al82 | 67 | BRCA1, 43 | 64 | 7/41 | 17 | 4/7 | 57 | + (41/67 cases) | No abnormalities detected in 25 standard protocol cases; two additional cases of primary peritoneal cancer detected in follow-up |
| BRCA2, 24 | 36 | ||||||||
| Meeuwissen et al83 | 133 | BRCA1/2, 86 | 65 | 1/133 | 0.75 | 1/1 | 100 | − | One additional case of primary peritoneal cancer detected in follow-up |
| Unknown, 47 | 35 | ||||||||
| Lamb et al84 | 113 | BRCA1, 40 | 35 | 7/113 | 6.2 | 5/7 | 71 | + | One of the two cases of malignancies that did not involve the FT was diagnosed as ovarian borderline adenofibroma with epithelial cytological atypia |
| BRCA2, 22 | 19 | ||||||||
| Not tested or no mutation, 51 | 45 | ||||||||
| Finch et al85 | 159 | BRCA1, 94 | 59 | 7/159 | 4.4 | 6/7 | 85 | + | |
| BRCA2, 65 | 41 | ||||||||
| Callahan et al86 | 122 | BRCA1, 60 | 49 | 7/122 | 5.7 | 7/7 | 100 | + | 6/7 (85%) of findings occurred in the fimbria, 1/7 involved the ampulla |
| BRCA2, 60 | 49 | ||||||||
| Not specified, 2 | 2 | ||||||||
Abbreviations: FT, fallopian tube; BSO, bilateral salpingo-oophorectomy; TIC, tubal intraepithelial carcinoma; NA, not available.